A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
121actual
Sites
51
Countries
Australia, Belgium, France +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-11 | actual | When the study began enrolling |
| Primary completion | 2025-07-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-10 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-18 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: PF-07220060
- Drug: letrozole — also filed as Femara
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14
measured Day 14
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-11-25 · 12.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-25 · 413 KB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed